Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Skin Swabs Could Detect Parkinson’s Years Before Symptoms Appear

By LabMedica International staff writers
Posted on 17 Jul 2025

Parkinson’s disease is notoriously difficult to diagnose in its early stages, as motor symptoms do not appear until later in the progression of the disease. More...

The ability to detect the disease up to seven years before symptoms emerge would be transformative, allowing for earlier interventions and improved outcomes. Traditional diagnostic methods do not identify Parkinson’s until physical symptoms manifest, leaving patients at a disadvantage. However, recent research has shown that the chemical composition of skin, specifically the sebum produced by the skin, contains biomarkers that may reveal signs of Parkinson’s disease in its earliest stages. Now, researchers have developed a novel non-invasive sampling method to detect these biomarkers, opening the door to earlier diagnosis of Parkinson’s.

Researchers at The University of Manchester (Manchester, UK) along with collaborators used a technique known as Thermal Desorption-Gas Chromatography-Mass Spectrometry (TD-GC-MS) to analyze skin swabs from participants with Parkinson’s disease, healthy controls, and individuals with isolated REM Sleep Behavior Disorder (iRBD), a condition often seen as an early warning sign of Parkinson’s. By analyzing the chemical profiles of the sebum, they were able to identify distinct biomarkers in individuals with iRBD, who had chemical profiles different from healthy controls but less pronounced than those with Parkinson’s. This technique revealed that Parkinson’s disease leaves a detectable trace on the body long before physical symptoms appear.

The findings of this study, published in the Journal of Parkinson’s Disease, showed that people with iRBD exhibited chemical profiles in their sebum that were distinct from healthy individuals, supporting the idea that Parkinson’s can be detected early. The team also discovered that this non-invasive method could be used to track the progression of Parkinson’s disease, offering the potential for regular monitoring and improved treatment outcomes. The results were validated when a trained "super smeller" was able to distinguish between Parkinson’s and iRBD in skin swabs. The next step in the research is to refine this method to make it a practical tool for clinical use, with further studies aimed at expanding its applications for other diseases.’

“This is the first study to demonstrate a molecular diagnostic method for Parkinson’s disease at the prodromal or early stage,” said Professor Perdita Barran, Professor of Mass Spectrometry at The University of Manchester. “It brings us one step closer to a future where a simple, non-invasive skin swab could help identify people at risk before symptoms arise allowing for earlier intervention and improved outcomes.”

Related Links:
University of Manchester


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Drug Testing Assays
Atellica DT 250 Analyzer
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.